Polymer-based siRNA delivery Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery

Purpose: Polymer-based siRNA delivery is promising but faces limitations similar to polymer-based DNA delivery, yet the two nucleic acids differ fundamentally in size, stiffness, stability, site of action, and duration of effect. This review addresses the need to understand these distinctions so that knowledge from the longer-studied field of polymeric DNA delivery can be adapted rationally to siRNA delivery.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central thesis is that siRNA and plasmid DNA share superficial similarities — both are anionic, double-stranded nucleic acids that can form polyplexes with cationic polymers — but their differences in molecular topography, complex size, degradation susceptibility, cellular target, and therapeutic duration require distinct delivery design considerations.

Aims: Compare siRNA and double-stranded DNA side-by-side in terms of molecular topography, complex size, duration of therapeutic effect, cellular location of activation, and degradation susceptibility. - Review factors governing polymer-mediated nucleic acid delivery, including the need for carriers, stable polymer–nucleic acid complex formation, surface charge, and physical/chemical stability. - Discuss polymer requirements for extracellular delivery, target-cell specificity and uptake, endosomal release, nucleic acid unpacking, and cytotoxicity. - Summarize polymeric siRNA carriers and highlight how DNA delivery knowledge can be applied to siRNA delivery.

Delivery system: Carrier class: Polymer-based gene delivery systems, especially cationic polymers. - Polymers discussed: Polyethylenimine (PEI; linear and branched), poly(L-lysine) (PLL), poly((2-dimethylamino)ethyl methacrylate) (PDMAEMA), chitosan, PLGA microspheres, poly(iso-butyl cyanoacrylate) nanocapsules, PEGylated polyplexes, histidylated PLL, disulfide cross-linked PEG-PLL, lactosylated triblock copolymer micelles. - Payloads: siRNA, plasmid DNA (pDNA), antisense oligodeoxynucleotides (ODNs). - Formulations: Polyplexes, nanoparticles, micelles, microspheres, aqueous-core nanocapsules. - Targeting ligands: Lactose, galactose, folate, peptides, proteins, antibodies. - Key design features: Electrostatic complexation, N/P ratio, PEGylation, disulfide cross-linking for redox-responsive release, pH-responsive endosomal escape, endosomolytic agents such as chloroquine.

Approach: Review of in vitro and in vivo literature. In vitro cell lines include HeLa, HEK293, MCF7, NIH/3T3, HuH-7, PC-3, MDA-MB-231, and others. In vivo examples include mouse tumor models and hepatocyte studies. No new primary experiments, group sizes, or doses are reported.

Key methods: Gel electrophoresis for polymer–nucleic acid binding and dissociation, including SDS competition. - Ethidium bromide exclusion assay for DNA condensation. - RNase protection and serum stability assays. - Dynamic light scattering and zeta potential for particle size and surface charge. - Transfection and gene silencing assays, including luciferase knockdown and β-galactosidase knockdown. - In vivo biodistribution and efficacy studies.

Key results: Persistence length: dsDNA ~50 nm; dsRNA ~70 nm. RNA is stiffer; 21 bp siRNA behaves as a rigid rod and is unlikely to condense further, risking incomplete encapsulation or large complexes. - Size limit: Non-specific cellular uptake via clathrin-coated pits is limited to ~150 nm. siRNA/PEI complexes greater than 150 nm were unable to mediate gene silencing in vitro. - Duration: Naked siRNA knockdown lasts 3–7 days in rapidly dividing cells, but longer than 3 weeks in slowly/non-dividing cells. Lipid encapsulation increased serum half-life from 0.8 h to 6.5 h. - PEGylation: PEI(25k)-g-PEG with 0.55 kDa PEG did not protect siRNA even at low RNase (0.6 mIU/µg); 2, 5, and 20 kDa PEG protected up to 6 mIU/µg. Knockdown increased up to 5 kDa PEG, with no further improvement above 5 kDa. - Unpacking: siRNA fully dissociated at sulfate/phosphate ratio (S/P) ≥ 8, whereas DNA did not dissociate until 10 < S/P ≤ 20, suggesting polycations bind more strongly to longer polyanions. - Cytotoxicity: Linear PEI 25 kDa IC50 = 19 µg/mL; branched PEI 0.8 kDa >50 µg/mL; branched PEI 22 kDa = 37 µg/mL. - Chitosan siRNA: Effective in vitro and in vivo carrier with no toxicity and gene silencing activity. - HIS-PLL: Achieved 90% gene silencing, not improved by chloroquine.

Interpretation: siRNA delivery faces many of the same barriers as DNA delivery, but fundamental differences — especially siRNA’s smaller size, greater stiffness, lower multivalency, and cytosolic site of action — mean that polymer design must be adjusted. Vector unpacking may be less problematic for siRNA than for DNA because siRNA forms less stable complexes with cationic polymers. Knowledge from DNA delivery can accelerate siRNA carrier development, but direct translation requires understanding these distinctions rather than assuming identical behavior.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Many comparisons between siRNA and DNA delivery remain theoretical or based on limited experimental data. - Cytotoxicity mechanisms of polycations are multifaceted and not fully delineated; polydispersity complicates toxicity interpretation. - Whether polycation toxicity differs between siRNA and pDNA delivery is an unanswered question. - In vivo data are limited; no large-animal or clinical validation is presented. - The review notes that the safe length threshold for siRNA-induced interferon responses is cell-type dependent, adding complexity.